Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(2.14)
# 2,693
Out of 4,784 analysts
488
Total ratings
32.86%
Success rate
-2.83%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCPH scPharmaceuticals | Reiterates: Buy | $18 | $2.78 | +548.65% | 14 | Mar 20, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $51 | $18.37 | +177.63% | 22 | Mar 19, 2025 | |
| CHRS Coherus BioSciences | Reiterates: Buy | $7 | $0.84 | +734.72% | 24 | Mar 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $54 → $80 | $48.88 | +63.67% | 30 | Mar 11, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $18 | $1.03 | +1,647.57% | 7 | Mar 7, 2025 | |
| EOLS Evolus | Reiterates: Buy | $27 | $12.05 | +124.07% | 26 | Mar 5, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $54 | $27.65 | +95.30% | 14 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $120 → $105 | $38.66 | +171.60% | 22 | Mar 3, 2025 | |
| APLS Apellis Pharmaceuticals | Reiterates: Buy | $57 | $24.27 | +134.86% | 26 | Mar 3, 2025 | |
| ARGX argenx SE | Maintains: Buy | $717 → $720 | $589.15 | +22.21% | 34 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $9.23 | +62.51% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $15.73 | +20.79% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.81 | +176.24% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $34.26 | +54.70% | 4 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $1.55 | +1,512.90% | 24 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $3 | $1.32 | +127.27% | 16 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.93 | +377.82% | 16 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $33.21 | +38.51% | 23 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $12 | $8.28 | +44.93% | 22 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.38 | +73.41% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $52.36 | +125.36% | 14 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $34.73 | +133.23% | 23 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $14.44 | +135.46% | 15 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.88 | +316.67% | 16 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.31 | +141.69% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.59 | +60,607.24% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $0.98 | +918.33% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $28.98 | -65.49% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $179.07 | +1.64% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $6.11 | +206.87% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $21.46 | -16.12% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $15.08 | -46.95% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $24.91 | +108.75% | 2 | Jun 11, 2019 |
scPharmaceuticals
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $2.78
Upside: +548.65%
Immunovant
Mar 19, 2025
Reiterates: Buy
Price Target: $51
Current: $18.37
Upside: +177.63%
Coherus BioSciences
Mar 11, 2025
Reiterates: Buy
Price Target: $7
Current: $0.84
Upside: +734.72%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $54 → $80
Current: $48.88
Upside: +63.67%
Neumora Therapeutics
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.03
Upside: +1,647.57%
Evolus
Mar 5, 2025
Reiterates: Buy
Price Target: $27
Current: $12.05
Upside: +124.07%
Biohaven
Mar 4, 2025
Reiterates: Buy
Price Target: $54
Current: $27.65
Upside: +95.30%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Buy
Price Target: $120 → $105
Current: $38.66
Upside: +171.60%
Apellis Pharmaceuticals
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $24.27
Upside: +134.86%
argenx SE
Feb 28, 2025
Maintains: Buy
Price Target: $717 → $720
Current: $589.15
Upside: +22.21%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $9.23
Upside: +62.51%
Feb 26, 2025
Reiterates: Buy
Price Target: $19
Current: $15.73
Upside: +20.79%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.81
Upside: +176.24%
Feb 24, 2025
Reiterates: Buy
Price Target: $53
Current: $34.26
Upside: +54.70%
Feb 18, 2025
Reiterates: Buy
Price Target: $25
Current: $1.55
Upside: +1,512.90%
Feb 18, 2025
Maintains: Buy
Price Target: $30 → $3
Current: $1.32
Upside: +127.27%
Feb 13, 2025
Reiterates: Buy
Price Target: $14
Current: $2.93
Upside: +377.82%
Feb 13, 2025
Reiterates: Neutral
Price Target: $46
Current: $33.21
Upside: +38.51%
Feb 12, 2025
Reiterates: Neutral
Price Target: $14 → $12
Current: $8.28
Upside: +44.93%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $10.38
Upside: +73.41%
Jan 21, 2025
Reiterates: Buy
Price Target: $118
Current: $52.36
Upside: +125.36%
Jan 13, 2025
Reiterates: Buy
Price Target: $81
Current: $34.73
Upside: +133.23%
Dec 17, 2024
Reiterates: Buy
Price Target: $34
Current: $14.44
Upside: +135.46%
Dec 17, 2024
Reiterates: Buy
Price Target: $12
Current: $2.88
Upside: +316.67%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $3.31
Upside: +141.69%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.59
Upside: +60,607.24%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $0.98
Upside: +918.33%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $28.98
Upside: -65.49%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $179.07
Upside: +1.64%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $6.11
Upside: +206.87%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $21.46
Upside: -16.12%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $15.08
Upside: -46.95%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $24.91
Upside: +108.75%